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ABSTRACT 
Objective: The present manuscript describes about simultaneous multiple response optimizations using the Derringer’s desirability function for the 
estimation of cefixime and ofloxacin in bulk and pharmaceutical dosage form by using HPTLC method. 
Methods: Central composite design (CCD) was used for the optimization of chromatographic conditions in HPTLC. The independent variables used 
for the optimization were n-butanol content in the mobile phase, chamber saturation time and distance travel. HPTLC separation was performed on 
aluminum plates pre-coated with silica gel 60 F 254 as the stationary phase using n-butanol: Ammonia: water (8:3:1 % v/v/v) as the mobile phase. 
Quantification was achieved by densitometric analysis of cefixime and ofloxacin over the concentration range of 20-120ng/band at 297 nm. 
Results: The method gave compact and well-resolved band at Rf of 0.43±0.02 and 0.73±0.02 respectively for cefixime trihydrate and ofloxacin 
hydrochloride. The linear regression analysis for the calibration plots showed r2 = 0.99985 and r2
Conclusion: The mobile phase composition, chamber saturation time and solvent front factors are evaluated in the robustness test. The selected 
factors were found to have a significant effect on the R
 = 0.9989 for cefixime and ofloxacin respectively. 
The optimized method complies validation parameters like precision, accuracy, robustness, specificity, limit of detection and limit of quantification 
as per ICH guidelines. 
f
Keywords: Cefixime, Ofloxacin, Central Composite Design (CCD), High-performance thin layer chromatography (HPTLC), Validation, Optimization 
 value of both drugs. The optimized method contains 7 ml of n-butanol, 75 mm solvent front 
and 33 min of saturation time was used. So the optimization process reduces the solvent usage and increases separation sensitivity for both drugs. 
The results indicate the CCD method is suitable for the routine quality control testing of marketed tablet formulation and bulk drugs. 
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
Cefixime is a semi synthetic, cephalosporin antibacterial. Chemically, 
it is (6R,7R)-7-[2-(2-Amino-4-hiazolyl)glyoxylamido]-8-oxo-3-vinyl-
5-thia-1-azabicyclo [4.2.0] oct-2ene-2-carboxylic acid, 72
Ofloxacin is a synthetic broad-spectrum antimicrobial agent for oral 
administration. Chemically, ofloxacin, is fluorinated carboxy-
quinolone, is the racemate, (±)-9-fluoro-2,3-dihydro-3-methyl-10-
(4-methyl-1-piperazinyl)-7oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine 
-6-carboxylic acid fig. 2. 
-(Z)-[O-
(carboxy methyl) oxime] trihydrate fig. 1. 
Cefixime (cephalosporin) and ofloxacin (fluoroquinolone) and has a 
unique dual mode of action i. e in this combination ofloxacin 
prevents nucleic acid synthesis of bacteria and cefixime inhibits 
bacterial cell wall synthesis. It is useful for killing the ESBL 
(Extended Spectrum Beta-lactamase) bacteria.  
 
 
Fig. 1: Molecular structure of Cefixime trihydrate [3] 
 
Both works instantly and synergistically and gives better patient 
compliance. Cefixime is highly stable in the presence of beta-
lactamases enzymes. Cefixime is an effective treatment to stop the 
spread of several bacterial infections. It is often used as a treatment 
for gonorrhea, pharyngitis, typhoid fever and tonsillitis. Ofloxacin 
belongs to fluoroquinolones group of antimicrobials (i.e.) these are 
the quinolones having one or more fluorine substitution in their 
structure. Ofloxacin used to treat pneumonia and bronchitis caused 
by H. influenzae and S. pneumoniae. It is also used in treating skin 
infections caused by staphylococcus aureus and streptococcus 
pyogenes bacteria [1-2]. 
 
Fig. 2: Molecular structure of ofloxacin [3] 
 
Literature survey states that cefixime and ofloxacin are official in IP, 
USP and BP individually [4] however, a combination of cefixime and 
ofloxacin is not official in any Pharmacopoeia. Various analytical 
methods like Spectrophotometry [8-13], HPLC [14-18], MASS 
Spectrometry [19], Spectroscopy [20] and Electrophoresis [21] 
methods were reported in the literature for the determination of 
cefixime and ofloxacin alone and in combination with other drugs in 
pharmaceutical dosage forms. However, development of a high-
performance thin-layer chromatographic (HPTLC) method for 
simultaneous estimation of cefixime and ofloxacin in combined 
dosage form has not been reported till date. 
The present manuscript is the first one that describes the method 
development and validation of HPTLC method as per ICH guidelines 
[5-7] ICH Q2 (R1) for simultaneous estimation of cefixime and 
ofloxacin. A multivariate approach using experimental design is used 
to study the simultaneous variation effect of the factors on the 
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responses. The best experimental design approach for the purpose 
of modeling and optimization is the response surface design. In the 
present study, central composite design (CCD) [22, 23] was used for 
optimization of chromatographic conditions of HPTLC method. CCD 
is chosen due to its flexibility and can be applied to optimize 
chromatographic conditions by gaining a better understanding of 
factor’s main and interaction effects. Viewing the simplicity, 
economical, less time-consuming and few processing parameters 
[24-26]. The objective of this research work is, to develop a simple, 
rapid, precise and accurate HPTLC method using Design of experiment 
(DOE) approach for quantitative analysis of cefixime and ofloxacin and 
to validate the developed method as per ICH guidelines. 
MATERIALS AND METHODS  
Materials 
The analytically pure cefixime and ofloxacin were obtained as gift 
samples from BAFNA pharmaceuticals Chennai. The Marketed tablet 
formulation used was Milixim-O, Glenmark, India, (Label claim: 200 
mg cefixime and 200 mg ofloxacin per tablet) procured from the 
local market. All solvents and chemicals used were of analytical 
grade, purchased from Merck Specialities Pvt. Ltd., India. 
Instrumentation 
• Hamilton microlitre syringe (Linomat syringe 659.0014, 
Hamilton-Bonaduz Schweiz, 
• Camag, Switzerland), 
• Precoated silica gel aluminum plate 60 F254, (10 × 10 cm, 100 
m thickness; E. Merck, Darmstadt, Germany), 
• Linomat 5 sample applicator (Camag,Switzerland), 
• Twin trough chamber (20 × 10 cm; Camag, Switzerland), 
• UV chamber (Camag, Switzerland), 
• TLC scanner 4 (Camag, Switzerland), 
• Win CATS version 1.4.6 software (Camag, Switzerland) was 
used in the study. 
All drugs and chemicals were weighed on an electronic balance 
(AUW 220, Shimadzu Corp., Japan). 
Methods 
Preparation of standard solutions 
Weigh specified the quantity of standard cefixime and ofloxacin 
were freshly prepared by using methanol and got 1 mg/ml. Aliquots 
of a standard stock solution of cefixime and ofloxacin were diluted to 
obtain the mixed standard solution by using the methanol to contain 
20 ng/µl of cefixime and ofloxacin. 
Preparation of mobile phase: [n-butanol: ammonia: water] 
(8:3:1%v/v) 
80 ml of N-butanol, 30 ml of ammonia and 10 ml of water were 
mixed and degassed in an ultrasonic water bath for 5 min. Then it 
was filtered through 0.45µ pore filter under vacuum and transferred 
into a 250 ml volumetric flask. 
Chromatographic procedure 
The standard solutions of cefixime and ofloxacin were spotted in the 
form of bands having a bandwidth of 6 mm using a Camag Linomat 
sample applicator. a pre-coated silica gel aluminum Plate 
60F[25]4
The length of chromatographic run was 8 cm. Subsequent to the 
development; HPTLC plates were dried in a current of air with the 
help of an air dryer. Densitometric scanning was performed using a 
Camag TLC scanner with winCATS software. All measurements were 
made in the reflectance–absorbance mode at 297 nm, slit dimension 
(6.00 x 0.30 mm, micro), scanning speed 20 mm/s, data resolution 
100 µm/step. The source of radiation was deuterium lamp emitting 
a continuous UV spectrum between 190 and 400 nm. Concentration 
of both drugs was determined from the intensities of diffusely 
reflected lights, and evaluation was done by ordinary linear 
regression analysis of peak areas 
are used as a stationary phase. Linear ascending 
development was carried out in a twin trough glass chamber. The 
mobile phase consists of n-butanol: ammonia: water (8:3:1, % 
v/v/v). The optimized chamber saturation time before 
chromatographic development was 30 min at room temperature 
(25±2 ◦C).  
Software aided method optimization 
Central composite design (CCD) was used to optimize the 
compositional parameters and to evaluate the main effect, 
interaction effects and quadratic effects of the factors on the 
retardation factor (Rf
The selection of critical factors and ranges examined for 
optimization was based on preliminary univariate studies of method 
development and chromatographic intuition. The composition of the 
mobile phase is the volume of n-butanol content with respect to 
total volume of the mobile phase. Totally fifteen experiments with 
five center points were conducted by selection of three factors, n-
butanol content in mobile phase (A), chamber saturation time (B), 
distance travel (C) and R
) of both drug. CCD is useful in response 
surface methodology, for exploring quadratic response surfaces and 
constructing second order polynomial models without the need to 
use a complete three-level factorial experiment [27, 28]. 
f
Method validation 
 of cefixime and ofloxacin were the 
responses selected for both drugs depicted in the table: 1. The 
nominal value for these all three factors, A, B and C were 8 ml, 30 
min, and 8 cm respectively. In context to this, n-butanol content (A) 
was kept between 6.59 and 9.41. Similarly, minimum and maximum 
values of chamber saturation time (B) were fixed as 22.93 min and 
37.07 min respectively. Likewise, minimum and maximum values for 
distance travel(C) were fixed as 6.59 and 9.41 respectively. The 
coded value of α is 1.41. The data generated were analyzed using 
Design Expert (Version 7.0.1.0 Stat-Ease Inc., Minneapolis, MN, USA) 
trial version statistical software. The significance of the relevant 
factors was calculated using Fisher’s statistical test for Analysis of 
Variance (ANOVA) model. All experiments were conducted in a 
randomized order to minimize the bias effects of uncontrolled 
variables. Replicates (n=5) of the center points were performed to 
estimate the experimental error. 
The developed HPTLC method was validated for accuracy, 
precision, limit of detection (LOD), limit of quantitation (LOQ), 
specificity, robustness, and ruggedness parameters, in accordance 
with ICH Q2 (R1). 
Linearity and range 
The mixed standard stock solution of 0.02 mg/ml of cefixime and 
0.02 mg/ml of ofloxacin was used for linearity studies. The 1 to 6 µl 
stock solution was spotted on the TLC plate to obtain the final 
concentration 20-120 ng/spot for both cefixime and ofloxacin. Each 
concentration was applied three times to the TLC plate. The plate 
was developed using the previously described mobile phase and the 
peak areas were plotted against the corresponding concentrations to 
obtain the calibration curve. The measured peak areas versus 
corresponding concentration of both drugs were evaluated by 
ordinary linear regression analysis. 
Sensitivity 
Limit of detection (LOD) and Limit of quantitation (LOQ) of the 
developed method was calculated from the standard deviation of the 
response and slope of the calibration curve of drugs using the 
formula as per ICH guideline, 
Limit of detection=3.3 × σ/S 
Limit of quantitation=10 × σ/S 
Where, “σ” is standard deviation of y-intercepts of regression lines, 
“S” is Slope of calibration curve. 
Precision 
The precision of the developed method was evaluated by performing 
Intra-day and Inter-day precision studies. Intra-day precision was 
carried out by performing three replicates of three different 
concentration (20, 40 and 60 ng/band for cefixime and ofloxacin) on 
same day and peak area measured was expressed in terms of 
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percent relative standard deviation (% RSD). The inter-day 
precision study was performed on three different days using 
mentioned concentrations of both drugs in triplicate 
Accuracy 
The accuracy of the method was ascertained in triplicates, at three 
concentration level of 50%, 75% and 100 %, by spiking known 
amount of cefixime and ofloxacin standard to the pre-quantified 
samples and calculating the recovery and % RSD for both the 
drugs. Recovery studies were carried out by spiking three 
different amount of cefixime and ofloxacin standard (20, 40, 60 
ng/band) to the dosage form (40 ng/band) by standard addition 
method. 
Specificity 
The specificity of the method was ascertained by comparing the 
samples of tablet formulation with standard drugs. The band for 
cefixime and ofloxacin in the sample was confirmed by comparing 
the Rf
Then 1 ml of the filtered solution was diluted to 10 ml to produce a 
concentration of 0.2 mg/ml or 200µg/ml for both cefixime and 
ofloxacin. Again the 1 ml of the above solution was diluted to 10 ml 
the concentration was obtained 20ng/ml. The final concentration 
obtained was 20 ng/spot for both cefixime and ofloxacin which was 
developed in an optimized mobile phase. The analysis was repeated 
in triplicate. The possibility of excipients interference with the 
analysis was examined. 
 and overlaying peak purity spectra with that of the standard. 
The peak purity of cefixime and ofloxacin was assessed by 
comparing the spectra at three different levels, i.e., peak start (S), 
peak apex(M) and peak end (E) positions of the band. 
Robustness 
The precision of the method was verified by repeatability and 
intermediate precision studies. Repeatability studies were 
performed by analysis of three different concentrations (20, 40, 60, 
ng/spot) for both drugs from the stock solution was applied at six 
times. The intra-day precision (RSD, %) was assessed by analyzing 
standard drug solutions within the calibration range, three times on 
the same day. Inter-day precision (RSD %) was assessed by 
analyzing drug solutions within the calibration range on three 
different days over a period of a week. 
The effect of small and deliberate variations on method 
parameters like a change in volume of n-butanol content in mobile 
phase composition, saturation time, distance travel and 
wavelength was evaluated. The effect of these changes on both the 
values and peak areas was examined by calculating the % RSD for 
each parameter 
Recovery 
Accuracy of the method was carried out by applying the method to 
the drug sample (cefixime and ofloxacin combination tablet) to 
which a known amount of cefixime and ofloxacin standard powder 
corresponding to 50, 75, 100, of label claim had been added 
(Standard addition method), mixed, and the powder was extracted 
and analyzed by running chromatogram in an optimized mobile 
phase. This process was done to check for the recovery of the drug at 
different levels in the formulation. 
Analysis of marketed formulation 
The content determination of cefixime and ofloxacin in a conventional 
tablet (Brand name: Milixim-O, Glenmark, India. (Label claim: 200 mg 
cefixime and 200 mg ofloxacin per tablet), the twenty tablets were 
weighed, and then the average weight was determined and finely 
powdered. The weight of the powdered tablet equivalent to 200 mg of 
cefixime and 200 mg of ofloxacin was transferred into a 100 ml 
volumetric flask. Then add 60 ml of methanol, sonicated for 30 min and 
diluted to 100 ml with methanol. The resulting solution was centrifuged 
at 3000 rpm for 15 min and the drug content of the supernatant liquid 
was determined (2 mg/ml for both cefixime and ofloxacin). 
RESULTS AND DISCUSSION 
Selection of wavelength 
The sensitivity of HPTLC method with ultraviolet detection 
depends on an appropriate wavelength. The developed plate was 
subjected to densitometric measurements in a scanning mode in 
the UV-Visible region of 200–700 nm, and the overlain spectrum 
was recorded on a CAMAG TLC Scanner 4. Both drugs absorbed 
appreciably at 297 nm, and selected as the detection wavelength 
fig. 3 overlain spectra. 
 
 




The optimizations of chromatographic conditions were done with a 
view to develop HPTLC method for simultaneous determination of 
cefixime and ofloxacin in bulk and in pharmaceutical dosage form. 
Preliminary study 
From the literature review, it is revealed that HPTLC method for 
cefixime and ofloxacin alone or with other drug combination had 
been reported, where selected mobile phase comprised of n-butanol, 
ammonia and water. Hence, various combinations of such 
components in different proportions such as n-butanol: ammonia: 
water (8:4:1 v/v); n-butanol: ammonia: :water (8:4:0.5, 7: 3: 0.5, 8: 
1: 1, 9: 1: 1, 8: 2: 0.5, v/v/v) were tried at fixed 30 min chamber 
saturation time and 80 mm solvent migration distance. However, 
satisfactory resolution of the drugs was not achieved with 
acceptable Rf value. Generally, chamber saturation time and solvent 
migration distance were crucial to HPTLC chromatographic 
separation. Here, chamber saturation time of less than 25 min and 
solvent migration distances greater than 80 mm resulted in the 
diffusion of the analyte band. n-butanol: ammonia: water (8: 2: 0.5, 
v/v/v) was found to be a satisfactory mobile phase, giving good 
separation of cefixime and ofloxacin. But, Rf value of ofloxacin was 
found to near 0.8 and was also affected by chamber saturation time. 
Therefore, further chromatographic conditions were optimized to 
obtain well-defined, compact bands of cefixime and ofloxacin with 
acceptable Rf
Central composite Design (CCD) is chosen due to its flexibility and 
can be applied to optimize HPTLC separation by gaining a better 
understanding of factor’s main and interaction effects. A three-
factorial, rotatable Central Composite statistical experimental design 
was performed using 15 experimental runs including five center 
points. The independent variables such as n-butanol content in 
mobile phase (A), chamber saturation time (B) and distance travel 
(C) and the responses for all 15 optimized trial experimental runs 
are summarized in table 1. During model selection, it was observed 
that the best-fitted model for R
 value (<0.8) of both drugs using CCD. 
Optimization of chromatographic conditions using CCD 
f
 
 of cefixime and ofloxacin was linear 
and quadratic model respectively based on lowest PRESS value and 
adjusted R2 value nearer to 1. 
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Table 1: Central composite rotatable design arrangement and responses 
Std Run Type of blocks Factor 1 
A: mobile phase in ml 
Factor 2 
B: saturation time in min 
Factor 3 




cefixime Rf ofloxacin 
12 1 Center 8.00 30.00 80.00 0.41 0.64 
2 2 Fact 9.00 25.00 90.00 0.17 0.53 
6 3 Axial 9.41 30.00 80.00 0.25 0.62 
1 4 Fact 9.00 35.00 70.00 0.58 0.75 
8 5 Axial 8.00 37.07 80.00 0.47 0.77 
13 6 Center 8.00 30.00 80.00 0.38 0.6 
7 7 Axial 8.00 22.93 80.00 0.73 0.85 
11 8 Center 8.00 30.00 80.00 0.46 0.74 
14 9 Center 8.00 30.00 80.00 0.45 0.71 
15 10 Center 8.00 30.00 80.00 0.43 0.67 
10 11 Axial 8.00 30.00 94.14 0.24 0.64 
9 12 Axial 8.00 30.00 65.86 0.68 0.97 
3 13 Fact 7.00 35.00 90.00 0.56 0.81 
4 14 Fact 7.00 25.00 70.00 0.57 0.88 
5 15 Axial 6.59 30.00 80.00 0.39 0.7 
 
The model was also validated by analysis of variance (ANOVA) 
using Design Expert software, and the results are as presented in 
table 2. Significant effects had P value less than 0.05. Adequate 
Precision, a measure of the signal (response) to noise ratio, 
greater than 4 is desirable, and the obtained ratio for both drugs 
indicated an adequate signal [21]. The coefficient of variation (% 
CV) that measures the reproducibility of the model less than 10% 
and high adjusted R-square values indicated a good relationship 
between the experimental data and those of the fitted models.  
Here, the adjusted R2 were well within acceptable limits of R2 ≥ 
0.80 which revealed the experimental data were a good fit to the 
polynomial equations [10]. The final equation, in terms of actual 
components and factors, is as shown in table 2. 
 
Table 2: Predicted response models and statistical parameters obtained from ANOVA for CCD 
Response(Rf Type of model ) Polynomial equation for Y Adjusted R2 Model P value % CV Adequate precision 
Cefixime 2FI Rf
-9.88269 















 ofloxacin = 
-0.028 * A 
-0.12 * C 
-0.044* A * B 
-0.038 * A * C 
+0.074 * B * C 
-0.021 * A2 
+0.054 * B2 
+0.051 * C2 
0.7502 0.0191 8.09 8.724 
*Result of predicted response are generated by Design Expert software 
 
A positive value represents an effect that favours the optimization, 
while a negative value indicates an inverse relationship between the 
factor and the response Three-dimensional Response surface plots 
and perturbation plots were constructed to evaluate the effect of the 
factors on the retention factor of each drug. In fig. 4, perturbation 
plots were presented for predicted model in order to gain a better 
understanding of the investigated procedure. It gives the idea about how 
the response changes as each factor moves from its defined reference 
value, with all other factors held constant at a reference point, and 
steepest slope or curvature indicates sensitiveness to a specific factor. 
Fig. 4 (a) shows that distance travel (factor C) had the most significant 
effect on Rf value of cefixime as compared to other factors. While in fig. 4 
(a) Solvent front (C) and chamber saturation time (B) had more 
significant effect on Rf value of cefixime followed by n-Butanol content 
(factor A). Fig. 4(b) represents a variation in Rf
 
 value of ofloxacin as a 
function of chamber saturation time and distance travel. The retention 
factor of ofloxacin decreases as travel distance increases but the 
saturation time increases the retention factor of ofloxacin also increases. 
Analysis of the perturbation plots and response plots of optimization 
model revealed that distance travel (C) and chamber saturation time (B) 
had a greater significant effect on responses of ofloxacin and cefixime as 
compared to factor A, i.e. n-butanol content. 
Fig. 4(a): Perturbation graph showing the effect of each factor A, 





A: Mob Phase = 8.00
B: Sat Time = 30.00
C: solvent Front = 80.00
Perturbation
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Table 3: Comparison of experimental and predictive values of different experimental runs under optimum conditions 
Optimum conditions Selected optimized run 





C: Distance Travel 
(Cm) 
 
Rf RValue of Cefixime f
Ofloxacin 
 Value of 








• Experimental Value 
• Predictive Value 
• Predicted Error 
2 7 ml 32 min 7.6 cm   
 • Experimental Value 
• Predictive Value 









Fig. 4(b): Perturbation graph showing the effect of each factor 
A, B, and C on Rf 
 
value of ofloxacin 
 
Three-dimensional plots of the RSM for both responses 
Fig. 5(a): Variation in Rf
 
 of Cefixime as function of B and C while 
fixed factor A; 
The optimum conditions of separation were estimated by 
Derringer’s desirability function. During numerical optimization, 
firstly the target of individual factors and responses were fixed. Out 
of 15 different solutions of optimization provided by software two 
conditions were selected that have desirability near to 1.  
The response surface obtained for the maximum Derringer’s 
desirability function is presented in fig. 5(a, b, C). 
 
Fig. 5(b): Variation in Rf
 
 of ofloxacin as function of A and B 
while fixed factor C 
 
Fig. 5(c): Graphical representation of the maximum derringer’s 
desirability function [D=0.870] 
 
In order to investigate the predictability of the proposed model, the 
agreement between experimental and predicted responses for both 
the predicted optimums 1 and 2 are shown in table 3. The 
Percentage of prediction error was calculated using formula, 
Predicted Error = Experimental-Predicted/Predicted × 100. 
From the table 3 and % predicted error, it is concluded that a set of 
coordinates producing high desirability value (D = 1) at optimum 
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condition for analyzing cefixime and ofloxacin in combination. The 
optimized composition selected was n-butanol: ammonia: water 
(7:2:1 v/v/v), for the final HPTLC analysis. HPTLC dendrogram 
under optimized conditions showing Rf of 0.43 for cefixime (40 
ng/band) and 0.73 for ofloxacin (40 ng/band) was depicted in fig. 6. 
The reported methods[17,20,21] shows the mobile phase 
composition was 8 ml of n-butanol and Rf value of ofloxacin was also 
more than 8 but the optimized method the mobile was composition 
was n-butanol: ammonia: water (7:2:1 v/v/v),distance travelled by 
solvent was 7.6 cm and Rf 
 
Fig. 6: HPTLC densitogram under optimized conditions showing 




Validation studies were conducted using the optimized assay 
conditions based on the principles of validation described in the ICH 
Q2A, QAB guidelines. Key analytical parameters including specificity, 
accuracy, precision, linearity, detection limit and quantification limit 
were evaluated. 
Linearity 
The linearity of an analytical method is its ability, within a given 
range, to provide results that are directly, or through a mathematical 
transformation, proportional to the concentration of the analyte. The 
cefixime and ofloxacin showed a good correlation coefficient (r2 = 
0.99985 for cefixime and r2 = 0.9923 for ofloxacin) in the proposed 
concentration range of 20-120 ng/band for both cefixime and 
ofloxacin (table 4).  
 
value ofloxacin was 0.73. So the optimized 
method required lesser analysis time and also produce the ideal, 
optimized densitogram for cefixime and ofloxacin. 
 
 
Fig. 7: Three-dimensional densitogram for linearity of Cefixime 
and Ofloxacin hydrochloride at 297 nm 
Table 4: Linearity studies of Cefixime trihydrate 
S. No. Concentration in ng/spot Mean peak area 
1 20 203268 
2 40 228623 
3 60 254025 
4 80 279328 
5 100 304830 
6 120 330440 
 
 
Fig. 8: Calibration curve of Cefixime (20-120ng/ml) 
 
Table 5: Linearity studies of Ofloxacin 
S. No. Concentration in ng/spot Mean peak area 
1 20 244268 
2 40 472330 
3 60 709992 
4 80 934354 
5 100 1165716 
6 120 1398051 
 
 
Fig. 9: Calibration curve of Ofloxacin (20-120ng/ml) 
 
LOD and LOQ 
LOD and LOQ of developed method were found to be 0.1076927 and 
0.3263416 ng/band respectively for cefixime while 0.223097ng/ml 
and 0.676053 ng/band respectively for ofloxacin indicating the 
sensitivity of the proposed method (table 6). 
Precision 
The experiment was repeated for three times in a day (Intra-day 
precision) and the average % RSD values of the results were 
calculated. Similarly, the experiment was repeated on three different 
days (Inter-day precision), and the average % RSD values for peak 
area of cefixime and ofloxacin was calculated. Results of intra-day 
and inter-day precision expressed in terms of % RSD less than 2 
confirm precision of the method (table 7). 
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Table 6: Analytical validation parameters for Cefixime and Ofloxacin by HPTLC method 
S. No. Parameter Cefixime Ofloxacin 
1 Linearity range(ng/band) 20-120 20-120 
2 Correlation coefficient (r2)* 0.99985 0.99923 
3 Slope±SD 1258.73±1.156 77.5856 
4 Confidence limit of slope* 1176.3-1287.63 22012.55556 
5 Intercept±SD* 177760.87 22012.555 
6 Confidence limit of intercept 176804.4-180226.33 21060.44-2341.32 
7 Sensitivity-LOD(ng/band)* 0.1076927 0.223097 
8 Sensitivity-LOQ(ng/band)* 0.3263416 0.676053 
9 Average of standard error 702.4742 11650.53 
*Average of five determinations 
 
Table 7: Precision studies for cefixime and Ofloxacin 
Drug name %RSD for interday precision* %RSD for intraday precision* Limit 
Cefixime 1.141-1.546 0.520-0.946 Less than 2 
Ofloxacin 1.538-1.788 0.754-1.203 
*mean±SD of three determinations for each concentration  
 
Accuracy 
The proposed method when used for evaluation of recovery at three 
concentrations levels, 
50%, 100% and 150% after spiking with standard, showed 
percentage recovery between 100.46 to 101.87 for cefixime and 
100.46 to 101.1.832 for ofloxacin which was within acceptable 
ranges of 100±2 %. 
Specificity 
The chromatogram of the pharmaceutical formulation using the 
developed method showed only two peaks at Rf of 0.34 and 0.77 for 
cefixime and ofloxacin respectively; that was found to be at the same 
Rf
Robustness 
 for both standard drugs by comparison of chromatograms (fig. 7). 
The peak purity of both drugs in pharmaceutical dosage form was 
confirmed when evaluated by comparing the overlaid spectra at 
peak start, peak apex and peak end positions of the band. It was 
observed from results shown in table 4 that purity was more than 
0.999 for all peaks, indicating the specificity of the method in the 
presence of various excipients (fig: 10 a and b). 
Deliberate change in different parameters like n-butanol content in 
mobile phase composition, chamber saturation time, distance travel 
and wavelength showed % Relative standard deviation of peak area 
less than 2%, indicating the robustness of method (table 9). 
  
Table 8: Accuracy studies for cefixime and Ofloxacin 
Spiked sample concentration at % level Cefixime* Ofloxacin* 
50 100.46±0.316 101.54±0.129 
75 101.87±1.832 101.43±1.689 
100 101.46±0.259 100.41±0.339 
*mean±SD of three determinations at each level 
 
Table 9: Robustness study of cefixime and ofloxacin by HPTLC method 
Change in mobile phase ratio (n-butanol: ammonia: Water, 8:2:0.5+0.25 in n-butanol content)* 
Drugs Ratio R % RSD f 
Ofloxacin  8.25: 2:0.5 0.76+0.01 0.546 
7.75: 2:0.5 0.76+0.01 1.736 
Cefixime 8.25: 2:0.5 0.46+0.01 0.510 
7.75: 2:0.5 0.46+0.01 0.668 
Change in chamber saturation time (30 min+5)* 
Drugs Saturation time (min) R % RSD f 
Ofloxacin  25 0.77+0.02 1.839 
 35 0.77+0.02 1.004 
Cefixime  25 0.44+0.02 1.492 
 35 0.47+0.02 1.192 
Change in Distance travel (8 cm+1)* 
Drugs Distance travel (cm) R % RSD f 
Cefixime 7 0.77+0.02 1.283 
 9 0.77+0.02 1.010 
Ofloxacin 7 0.43+0.02 1.027 
 9 0.44+0.02 0.893 
Change in wavelength (297 nm+2)* 
Drugs Wavelength (nm) R % RSD f 
Ofloxacin 299 0.76+0.02 0.506 
 295 0.76+0.02 0.246 
Cefixime 299 0.45+0.02 0.313 
 295 0.45+0.02 0.809 
mean±SD of three determinations of 40 ng/band for Cefixime and 40 ng/band for Ofloxacin, % RSD = relative standard deviation, 
Sumithra et al. 







Fig. 10: Overlain peak purity spectra of (a) Cefixime and (b) 
Ofloxacin with the corresponding standard 
 
Analysis of marketed dosage form 
Analysis of tablet formulation containing 200 mg cefixime and 200 
mg ofloxacin showed good recovery for both drugs. The %RSD value 
was found to be less than 2 indicating that the method can be 
applicable in routine quality control testing of the tablet dosage 
formulation. 
 
Table 10: Assay of formulation (Cefixime 200 mg and Ofloxacin 
200 mg) 
Sample No Cefixime amounts in 
% 
Ofloxacin amount in 
% 
I 101.46 100.54 
II 100.87 102.43 
III 99.46 101.41 
IV 99.92 101.23 
V 99.63 99.45 
SD 0.86085 1.0044 
%RSD 0.85855 1.0993 
  
CONCLUSION 
The CCD design provides essential information regarding the 
sensitivity of various chromatographic variables such as Rf value of 
drugs, mobile phase composition, chamber saturation time and 
distance travel. The CCD design and multi-criteria decision-making 
approach is a flexible procedure, able to reduce the number of the 
needed experiments for the development and optimization of HPTLC 
method and it is an economical method that can be used to generate 
a maximum amount of information in a lesser analysis time with a 
small number of experiments. The optimized method the mobile 
phase composition was n-butanol: ammonia: water (7:2:1 v/v/v), 
distance travelled by solvent was 7.6 cm and Rf 
CONFLICT OF INTERESTS 
value ofloxacin was 
0.73. So the optimized method required only lesser analysis time 
compare to reported method and also produce the ideal, optimized 
densitogram for cefixime and ofloxacin. The established HPTLC 
method is simple, accurate, and reliable and suitable for rapid 
quantitative analysis of cefixime and ofloxacin. So the proposed 
HPTLC method can be successfully utilized for the simultaneous 
estimation of cefixime and ofloxacin in the pharmaceutical dosage 




1. http://www.drugbank.ca/drugs/DB00671. [Last accessed on 
10 Jan 2016]. 
2. https://en.wikipedia.org/wiki/Cefixime. [Last accessed on 10 
Jan 2016]. 
3. https://en.wikipedia.org/wiki/Ofloxacin. [Last accessed on 10 
Jan 2016].  
4. Indian Pharmacopoeia: Ministry of Health and Family Welfare, 
Indian Pharmacopoeial commission, Ghaziabad; 2014. p. 254, 856. 
5. ICH Topic Q8 (R2); “ICH harmonised tripartite guideline,” in 
Proceedings of the International Conference on Harmonisation 
of Technical Requirements for Registration of Pharmaceuticals 
for Human Use (ICH ’09): Pharmaceutical Development; 2009. 
6. ICH Topic Q2 (R1); “ICH harmonised tripartite guideline,” in 
Proceedings of the International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH ’94): Validation of Analytical Procedures; 1994.  
7. ICH Topic Q9;“ICH harmonised tripartite guideline,” in 
Proceedings of the International Conference on Harmonisation 
of Technical Requirements for Registration of Pharmaceuticals 
for Human Use (ICH ’94) Quality Risk Management; 2005. 
8. Attimarad M. Simultaneous determination of ofloxacin and 
flavoxate hydrochloride by first and ratio first derivative UV 
spectrophotometry. J Iranian Chem Soc 2012;9:1–7. 
9. Gonzalez-Hernandez R, Nuevas-Paz L, Soto-Mulet L, Lopez-
Lopez M, Hoogmartens J. Reversed-phase high-performance 
liquid chromatographic determination of cefixime in bulk 
drugs. J Liq Chromatogr Relat Technol 2001;24:2315–24. 
10. Pawar SJ, Kale AP, Amrutkar MP, Jagade JJ, Pore NS, Bhosale AV. 
HPTLC estimation of cefixime and cloxacillin in tablet dosage 
form. Asian J Res Chem 2010;3:299–301. 
11. Chaitanya Krishna A, Vignesh R, Chelladurai R, Rajaram S Patil. 
A highly specific, sensitive and high-throughput method for the 
determination of ofloxacin in human plasma by liquid 
chromatography coupled with tandem mass. Asian J Pharm Clin 
Res 2012;5:174-9.  
12. Umamaheswari D, Jayakar B. Analytical method development, 
and validation for the simultaneous estimation of nimorazole 
and ofloxacin in pure and its pharmaceutical dosage form by 
RP-HPLC. Asian J Pharm Anal Med Chem 2014;2:268-75. 
13. Prabhu S, Vijay Amirtharaj R, Senthilkumar N. Simultaneous RP-
HPLC method development and validation of cefixime and 
ofloxacin in tablet dosage form. Asian J Res Chem 2010;3:367-9. 
14. Khandagle KS, Gandhi SV, Deshpande PB, Kale AN, Deshmukh 
PR. High-performance liquid chromatographic determination 
of cefixime and ofloxacin in combined tablet dosage form. J 
Chem Pharm Res 2010;2:92-6. 
15. Mahesh V Attimarad, Ahmed O Alnajjar. A conventional HPLC-
MS method for the simultaneous determination of ofloxacin 
and cefixime in plasma development and validation. J Basic Clin 
Pharm 2013;4:36–41. 
16. D Zendelovska, T Stafilov, P Milosevski. A high-performance 
liquid chromatographic method for determination of cefixime 
and cefotaxime in human plasma. Bull Chem Technol Maced 
2003;22:39-45. 
17. Rao J. Validated HPTLC method for simultaneous quantitation 
of cefixime and ofloxacin in bulk drug and in a pharmaceutical 
formulation. Pharmacie Globale (IJCP) 2011;4:1-5. 
18. Patel Satish A, Patel Natavarlal J. Development and validation of 
RP-HPLC method for simultaneous estimation of cefixime 
Sumithra et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 7, 200-208 
 
208 
trihydrate and ofloxacin in tablets. Int J Pharm Res Biosci 
2012;1:516-29. 
19. Meng F, Chen X, Zeng Y, Zhong D. Sensitive liquid 
chromatography-tandem mass spectrometry method for the 
determination of cefixime in human plasma: application to a 
pharmacokinetic study. J Chromatogr B: Anal Technol Biomed 
Life Sci 2005;819:277-82. 
20. Audumbar Digambar Mali, Ritesh Bathe, Ashpak Tamboli. 
21. Ao Alnajjar. Simultaneous determination of ofloxacin and 
cefixime in tablet formulation using capillary electrophoresis. J 
Liq Chromatogr Relat Technol 2013;36:36-41. 
Simultaneous determination of Cefixime trihydrate and 
Ofloxacin in pharmaceutical dosage form by second order 
derivative UV spectrophotometry. Int J Adv Pharm Anal 
2015;(5 Suppl 2):42-6. 
22. P Borman, P Nethercote, M Chatfield. The application of quality 
by design to analytical methods. PharmTech; 2007. 
23. MM Hendriks, JH De Boer, AK Smilde, DA Doornbos. Multicriteria 
decision making. Chemom Intell Lab Syst 1992;16:175-91. 
24. T Sivakumar, R Manavalan, K Valliappan. Global optimization 
using derringer’s desirability function: Enantioselective 
determination of ketoprofen in the formulation and in 
biological matrices. Acta Chromatogr 2007;19:29-47. 
25. V Sree Janardhanan, R Manavalan, K Valliappan. Chemometric 
technique for the optimization of the chromatographic system. 
Simultaneous HPLC determination of Rosuvastatin, 
Telmisartan, Ezetimibe and Atorvastatin used in combined 
cardiovascular therapy. Arabian J Chem 2012;1-10. 
Doi:10.1016/J.Arabjc.2012.03.001. [Article in Press] 
26. TB Solanki, PA Shah, KG Patel. Central composite design for 
validation of HPTLC method for simultaneous estimation of 
olmesartan medoxomil, amlodipine besylate and 
hydrochlorothiazide in tablets. Indian J Pharm Sci 2014;76:179-87. 
27. JH Zar. Biostatical analysis: Pearson Education Inc. New Jersey; 
2010. 
28. G Kleinschmidt. In: Ermer J, Miller JHM. Eds. Method validation 
in pharmaceutical analysis. A Guide to Best Practice, Wiley-VCH 
Verlag GmbH and Co. KGaA, Weinheim; 2005. 
 
